The COVID-19 Treatment Guidelines Panel (the Panel) is pleased to announce the publication of an updated version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

In the United States, the prevalence of SARS-CoV-2 Omicron subvariants that are not susceptible to tixagevimab plus cilgavimab (Evusheld) is now more than 90%.

Because of this, tixagevimab plus cilgavimab is not authorized for use as COVID-19 pre-exposure prophylaxis (PrEP) in the United States.

The Panel now recommends against the use of tixagevimab plus cilgavimab as COVID-19 PrEP.

Several sections of the Guidelines have been revised to reflect this recommendation, including Testing for SARS-CoV-2 Infection, Prevention of SARS-CoV-2 Infection, and many of the sections in Special Populations.

Read More